Sage Therapeutics, Inc.
SAGEDelisted Jul 31, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597553
Sage Therapeutics, Inc. was delisted on Jul 31, 2025; its insiders filed their last Form 4 on Jul 31, 2025; 192 institutions reported holding it in 13F filings for Q2 2025, worth $445.6M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 192
- Q2 2025, −5 vs. previous quarter
- 13F value
- $445.6M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- $41.2M
- −52.3% year over year
- Net income, FY2024
- -$400.7M
- No comparable prior period
- Free cash flow, FY2024
- -$267.2M
- No comparable prior period
- Revenue, Q2 FY2025
- $31.7M
- +265.8% year over year
Revenue flow, FY2024
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2024: $400.7M (971.5% of revenue).
Superinvestors holding SAGE, Q2 2025
Go to the superinvestors tabNo superinvestor reported holding SAGE at the end of Q2 2025.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Sage Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | Barrett ElizabethDirector | PPurchase | +2.00K | $18.64 | +$37.3K | +200.0%3.00K after | |
| May 11, 2023 (view filing) | May 9 | 2 days | Barrett ElizabethDirector | PPurchase | +1.00K | $50.50 | +$50.5K | New position1.00K after | |
| Feb 10, 2023 (view filing)4:42 PM ET | Feb 10 | Same day | Jonas Jeffrey MDirector | SSale | −11.6K | $44.61 | −$519.4K | −8.7%122.0K after | 2 lots |
| Nov 15, 2022 (view filing) | Nov 10 | 5 days | Greene Barry EPresident and CEO | PPurchase | +14.5K | $34.48 | +$500.0K | +44.7%46.9K after | |
| May 9, 2022 (view filing) | May 5 | 4 days | Golumbeski GeorgeDirector | PPurchase | +8.00K | $31.45 | +$251.6K | New position8.00K after | |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Greene Barry EPresident and CEO | PPurchase | +23.6K | $43.15 | +$1.02M | +268.6%32.4K after |
Top 10 13F holders, Q2 2025
See all 192 holdersThe largest institutional positions in Sage Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 6,077,065 | $55.4M | 3.70% | +1,599,267+35.7% | Added |
| BlackRock, Inc. | 4,545,458 | $41.5M | 0.00% | −115,614−2.5% | Reduced |
| Vanguard Group Inc | 3,265,802 | $29.8M | 0.00% | −1,811,486−35.7% | Reduced |
| Hudson Bay Capital Management LP | 1,952,245 | $17.8M | 0.12% | +1,372,672+236.8% | Added |
| D. E. Shaw & Co., Inc. | 1,917,284 | $17.5M | 0.02% | −170,159−8.2% | Reduced |
| Balyasny Asset Management LLC | 1,518,170 | $13.8M | 0.03% | +1,404,441+1,234.9% | Added |
| Geode Capital Management, LLC | 1,356,577 | $12.4M | 0.00% | +53,200+4.1% | Added |
| Alpine Associates Management Inc. | 1,273,348 | $11.6M | 0.62% | +1,273,348 | New |
| State Street Corp | 1,166,002 | $10.6M | 0.00% | −22,572−1.9% | Reduced |
| 683 Capital Management, LLC | 1,150,000 | $10.5M | 1.06% | +150,000+15.0% | Added |
Holders of 5% or more of SAGE
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Sage Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.20%4.43M shares | – | Oct 21, 20243 filings | Apr 17, 2025 | SEC |
| Vanguard Group Inc | 13G/A | 5.21%3.27M shares | −2.69 ppfrom 7.90% | Feb 10, 202110 filings | Jul 29, 2025 | SEC |